Show simple item record

dc.contributor.authorGudjonsson, H
dc.contributor.authorOddsson, E
dc.contributor.authorThjodleifsson, B
dc.date.accessioned2011-02-02T11:52:20Z
dc.date.available2011-02-02T11:52:20Z
dc.date.issued1994
dc.date.submitted2011-02-02
dc.identifier.citationDigestion.1994, 55(6):395-8en
dc.identifier.issn0012-2823
dc.identifier.pmid7705552
dc.identifier.doi10.1159/000201171
dc.identifier.urihttp://hdl.handle.net/2336/120932
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe objective of the study was to assess whether sucralfate can prevent or diminish short-term nonsteroidal anti-inflammatory drug (NSAID)-induced damage in the stomach and duodenum. Sixteen healthy subjects were randomly treated for 7 days with sucralfate 2 g b.d. or placebo in a double-blind cross-over manner. Naproxen 500 mg b.d. was given on days 3-7. Gastrointestinal endoscopy was performed before and after each treatment period. Mucosal damage was measured by counting erosions, submucosal hemorrhages or ulcers on a fixed point scale of 0-4 for stomach and duodenum separately. The mean posttreatment injury score in the stomach was 2.13 +/- 1.51 and 2.0 +/- 0.97 for the placebo and sucralfate periods, respectively (p = 0.72). The possibility of type II error was 7%. In the duodenum, the injury score was 1.69 +/- 1.08 and 1.06 +/- 0.93 for the placebo and sucralfate periods, respectively (p = 0.08). The possibility of type II error was 37%. Sucralfate has no efficacy as a prophylactic agent against short-term NSAID-induced gastroduodenal injury.
dc.language.isoenen
dc.publisherKargeren
dc.relation.urlhttp://dx.doi.org/10.1159/000201171en
dc.subject.meshAdulten
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidalen
dc.subject.meshCross-Over Studiesen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshDrug Interactionsen
dc.subject.meshDuodenumen
dc.subject.meshFemaleen
dc.subject.meshGastric Mucosaen
dc.subject.meshGastrointestinal Diseasesen
dc.subject.meshHumansen
dc.subject.meshIntestinal Mucosaen
dc.subject.meshMaleen
dc.subject.meshStomachen
dc.subject.meshSucralfateen
dc.titleDoes sucralfate prevent short-term NSAID induced damage to the gastroduodenal mucosa?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Landspítalinn, National Hospital, Reykjavík, Iceland.en
dc.identifier.journalDigestionen
html.description.abstractThe objective of the study was to assess whether sucralfate can prevent or diminish short-term nonsteroidal anti-inflammatory drug (NSAID)-induced damage in the stomach and duodenum. Sixteen healthy subjects were randomly treated for 7 days with sucralfate 2 g b.d. or placebo in a double-blind cross-over manner. Naproxen 500 mg b.d. was given on days 3-7. Gastrointestinal endoscopy was performed before and after each treatment period. Mucosal damage was measured by counting erosions, submucosal hemorrhages or ulcers on a fixed point scale of 0-4 for stomach and duodenum separately. The mean posttreatment injury score in the stomach was 2.13 +/- 1.51 and 2.0 +/- 0.97 for the placebo and sucralfate periods, respectively (p = 0.72). The possibility of type II error was 7%. In the duodenum, the injury score was 1.69 +/- 1.08 and 1.06 +/- 0.93 for the placebo and sucralfate periods, respectively (p = 0.08). The possibility of type II error was 37%. Sucralfate has no efficacy as a prophylactic agent against short-term NSAID-induced gastroduodenal injury.


This item appears in the following Collection(s)

Show simple item record